{
  "abstract": "Malnutrition (MN) affects 50–80% of patients with cancer and is associated with altered body composition, impaired functional status and poor oncological outcomes for antineoplastic drug therapies, radiation and surgery. These outcomes include earlier death, excess symptom burden, higher costs, poor mobility and worse quality of life.1 MN can be characterised by unintentional weight loss, which may be evident even before any cancer treatment. MN occurs along a spectrum, wherein the cancer cachexia syndrome is the most severe.2 Validated tools exist to screen for MN risk throughout the cancer care continuum but are underused.3",
  "authors": [
    {
      "affiliations": [
        "Supportive Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA"
      ],
      "name": "Ye Myint Aung"
    },
    {
      "affiliations": [
        "Supportive Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA"
      ],
      "name": "Aynur Aktas"
    },
    {
      "affiliations": [
        "Internal Medicine, Atrium Health, Charlotte, North Carolina, USA"
      ],
      "name": "Vishal Shroff"
    },
    {
      "affiliations": [
        "Solid Tumor Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA"
      ],
      "name": "Kunal Kadakia"
    },
    {
      "affiliations": [
        "Supportive Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA"
      ],
      "name": "Jake Waldman"
    },
    {
      "affiliations": [
        "Supportive Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA",
        "Hemby Family Foundation Endowed Chair in Supportive Oncology, Levine Cancer Institute, Charlotte, North Carolina, USA"
      ],
      "name": "Declan Walsh"
    }
  ],
  "title": "Nutrition assessment defects in cancer clinical trials",
  "uid": "9e9e5a18-eb36-562e-be0e-0d65e3ff69ac"
}